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Continuous treatment with tyrosine kinase inhibitors (TKI) induces a fast initial response and 
leads to long-term remission in most patients with chronic myeloid leukaemia (CML) 1. 
Consequently, the annual mortality in CML has decreased to 1–2% 2 and patients with CML 
approach the life expectancy of the general population 3. However, continuous treatment with 
TKI is costly and associated with significant side effects. Therefore, alternative treatment 
strategies are needed. Although TKI dose reductions during established molecular remission 
have only been considered recently 4,5, the potential of TKI treatment cessation for CML 
patients in sustained molecular remission has been studied in greater detail 6,7. Several 
studies consistently report that about 50% of CML patients remain in treatment-free 
remission (TFR) for many years while most of the other patients present with recurring 
disease levels after stopping TKI 8,9. Although TKI treatment duration and time in molecular 
remission are associated with higher TFR rates 9, a reliable prospective prediction of disease 
recurrence for individual patients is not possible yet. The DESTINY trial (NCT01804985) 
differs from other TKI stop studies in that TKI treatment is reduced to 50% of the standard 
dose for 12 months prior to cessation, including 125 patients in stable MR4 (BCR-ABL1IS 
<0.01%) and 49 patients in stable MR3 (BCR-ABL1IS <0.1%) but not MR4 before entry. The 
trial demonstrates that this strategy improves the fraction of MR4 patients in successful TFR 
to above 70% at 2 years after treatment cessation while also about 36% of MR3 patients 
retained TFR 10,11. Here, we evaluate the BCR-ABL1IS values monitored during dose 
reduction and suggest that they can serve as a predictor of individual CML recurrence after 
TKI cessation independent of the BCR-ABL1IS values at study entry. 
 
BCR-ABL1IS levels are regularly obtained from peripheral blood cells of CML patients to 
monitor their leukaemia load. Within DESTINY, BCR-ABL1IS was available for all 174 
patients measured prior to dose reduction (time point 0), monthly during the 12 months dose 
reduction period and monthly or every second month thereafter until month 36. Molecular 
recurrence was defined as the first of two consecutive BCR-ABL1IS measurements >0.1% or 
using particular case reports indicating recurrences without achieving BCR-ABL1IS >0.1%. In 
total, 67 recurrences were observed of which 12 occurred during the dose reduction period. 
At recurrence, TKI treatment at full dose was reinitiated. In order to quantify the change of 
BCR-ABL1IS during the 12 months dose reduction period, we applied a linear regression to 
each patient and estimated the individual slope measured on the log[BCR-ABL1IS] scale 
(Figure 1A), if at least 3 non-zero BCR-ABL1IS values were available. Thereby we excluded 3 
of 174 patients. The correlation of individual slopes and molecular recurrence was quantified 
by logistic regression analysis. 
 
We observed that the majority of patients had either negative slopes (i.e. BCR-ABL1IS 
decreasing) or low positive slopes close to zero (Figure 1B), indicating that their BCR-ABL1IS 
levels did not rise substantially, if at all, during the dose reduction period. In contrast, there is 
a group of patients with considerably higher slopes, indicating an increase in BCR-ABL1IS. 
Logistic regression analysis shows that for an additional 0.01 log[BCR-ABL1IS] increase per 
month in the slope parameter, there was a 28% increased chance of recurrence (Odds Ratio 
(OR): 1.28; 95% CI: 1.17-1.42) at any time (Figure 1C). This also applies if the MR3 and 
MR4 subgroups are analysed separately (Supplemental Figure 1) and indicates that an 
increase of BCR-ABL1IS during the dose reduction period is strongly associated with 
eventual molecular recurrence.  
 
We identified the 95%-quantile of a normal distribution fitted to the negative/low BCR-ABL1IS 
slopes at 0.068 log[BCR-ABL1IS] increase per month as a suitable cut off to split the patient 
cohort into 80.7% with negative/low slopes and 19.3% with high slopes (Figure 1B, 
Supplemental Material). Irrespective of the response level prior to dose reduction, 72.5% of 
the patients presenting with a negative/low slope during dose reduction remained 
recurrence-free at 2 years after stopping treatment. In the high slope group, 87.9% of the 
patients had disease recurrence, while only 4 patients (12.1%) did not report the adverse 
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(95% CI: 6.3-57.9, Figure 1D) indicating that the risk of recurrence is dramatically increased 
for the high slope group compared to the group with negative/low slopes.  
 
Almost all TFR studies hitherto have focussed on patients in stable MR4 while the DESTINY 
trial also included 49 MR3 patients. Having a closer look at their response during dose 
reduction separately, it appears that 30.6% of the MR3 patients presented with high slopes, 
while only 14.8% of the patients in MR4 showed similarly elevated slopes. I.e., patients in 
MR3 have a 2.6-fold higher chance to present with highly increasing BCR-ABL1IS levels 
during dose reduction compared to patients in MR4 (OR: 2.6, 95% CI:1.2-5.6).  
 
Although less common than with high slopes, recurrences after stopping TKI nevertheless 
occurred in patients with negative/low slopes during the dose reduction period in both the 
MR3 and MR4 cohorts. A detailed analysis of the distribution of the individual slopes of those 
patients (Figure 2A) reveals that there is a tendency for lower slopes in the remission cohort 
as compared to the recurrence cohort, thereby underpinning our findings of the overall 
logistic regression model.  
 
Our findings suggest an amended strategy for TKI cessation studies, exploiting additional 
information from intermediate dose reduction: After the 12 months dose reduction period, 
patients should only be stopped if they are still below MR3 (i.e. no early recurrence) and 
additionally show a negative/low BCR-ABL1IS slope during this period. Patients with high 
slopes should return to full dose TKI treatment, as a future recurrence is extremely likely and 
they do not even sufficiently manage the half dose reduction. Enforcing such a strategy 
within the DESTINY protocol could have further increased the fraction of recurrence-free 
patients among those patients that stopped TKI after the 12 months dose reduction (Figure 
2B). For completeness we note that patients with continuing negative BCR-ABL1IS 
measurements are rare within DESTINY but might occur more often in other cessation 
studies with more stringent entry criteria. While we exclude such patients (n=3) from our 
analysis, this cohort might have to be considered separately in future studies. However, as 
long as no measurable increase of BCR-ABL1IS levels can be detected, those patients are 
not considered as high risk anyway. 
 
From our analysis we conclude that the individual molecular dynamic during TKI dose 
reduction is a promising predictor for a molecular recurrence after TKI cessation. In 
particular, the exclusion of patients with highly increasing BCR-ABL1IS slopes during the 
dose reduction period from complete TKI cessation is likely to reduce the overall number of 
recurrences, and to increase the TFR success rate on stopping TKI. For the clinical decision 
about whether to stop TKI treatment after the dose reduction period, we have estimated the 
positive predictive value (i.e. probability of losing TFR for patients with high slope) and the 
negative predictive value (i.e. probability of keeping TFR for patients with negative/low slope) 
to be 81.0% and 72.5%, respectively, based on the 159 DESTINY patients at risk at month 
12 and a recurrence prevalence of 34.6%. Conceptually, our results demonstrate that 
frequent monitoring of molecular response during dose reduction can inform patient 
management by minimising the risk for CML recurrence on a subsequent TFR attempt. A 
validation of our quantitative estimates using an independent cohort is necessary to confirm 
our predictions and to compare or complement our approach with further biomarkers of TFR. 
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Figure 1: BCR-ABL1IS level monitored during dose reduction are predictive for 
individual CML recurrence after TKI cessation. 
(A) BCR-ABL1IS dynamics of two patients upon dose reduction. The left example 
corresponds to a patient with a low positive slope of the BCR-ABL1IS values during dose 
reduction period (green line indicates the slope) that remains in TFR after therapy stop. The 
right example illustrates a patient who is characterized by a high slope during the 12 months 
dose reduction period (red line) and presents with a recurrence after TKI stop (red dots).  
(B) Histogram for patient-specific estimates of the individual BCR-ABL1IS slope during the 12 
months dose reduction period (n=171). The 95%-quantile (red dashed line) of the normal 
distribution fitted to patients with negative/low slope (green curve) is taken as a cut-off 
parameter (at 0.068 log[BCR-ABL1IS] per month) to separate patients with high slopes (red 
curve).  
(C) Logistic regression curve for patient-specific estimates of the individual BCR-ABL1IS 
slope during the 12 months dose reduction period (n=171) with corresponding odds ratio 
(OR) and 95% confidence interval (CI) per 0.01 log-increase per month. Patients are 
separated into cohorts with negative/low slopes (green area) and patients with high slopes 
(red area) by applying the cut-off parameter announced in (B). 
(D) Fraction of patients with and without recurrence in the cohorts with negative/low and high 
slopes during dose reduction (n=171) and corresponding odds ratio (OR) with 95% 
confidence interval (CI). 
 
Figure 2: Subgroup and recurrence-free survival analysis.   
(A) Subgroup analysis of the patients with negative/low slope (n=138): The central part 
reproduces an inset of the logistic regression curve for patient-specific estimates of the 
individual BCR-ABL1IS slope during the 12 months dose reduction period. Patients are 
categorized according to their prior BCR-ABL1IS level as either MR3 (rhombi) or MR4 (filled 
circles). The upper and lower panel depict the slope distributions of patients with and without 
molecular recurrence, respectively, stratified for the molecular response level before dose 
reduction (i.e. MR3: dark shaded, MR4: light shaded). Small ticks indicate the estimates of 
the individual BCR-ABL1IS slopes and black bars illustrate the mean of the slope of the 
respective group (upper panel: mean of MR3 recurrence group = 0.017 and MR4 recurrence 
group = 0.014; lower panel: mean of MR3 non-recurrence group = -0.005 and MR4 non-
recurrence group = 0.006). 
(B) Recurrence-free survival of patients with either negative/low (green) or high slope (red) 
during the 12 months reduction period (n=171). The patients with high slopes are further 
separated as to whether they present with disease recurrence during the half dose period 
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